RxDoctor Payments Data

Richard Bloomingdale, MD

Internal Medicine · Royal Oak, MINPI 1245573716

Payments from drug & device makers

$7,492in general payments, 2019–2025

Across 103 payments — averaging $72.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$5K
  • Boston Scientific$875
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$623
  • Amgen$418
  • Abbott$316
  • E.r. Squibb & Sons, L.L.C.$139
  • plus $464 from 9 others

What the payments were for

  • Speaking & faculty fees$1222%
  • Travel & lodging$3,75750%
  • Food & beverage$3,34345%
  • Education$2704%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,492 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$117,616
Medicare patients
976
Services billed
1,673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban166$206,543
Repatha SureclickEvolocumab178$98,927
JardianceEmpagliflozin47$60,625
XareltoRivaroxaban41$53,469
EntrestoSacubitril/Valsartan34$41,129
FarxigaDapagliflozin Propanediol18$20,078
Rosuvastatin Calcium281$5,684
Metoprolol Succinate186$3,502
CorlanorIvabradine Hcl12$3,229
Atorvastatin Calcium191$3,093
Carvedilol161$2,662
Ezetimibe83$2,034
Nifedipine ErNifedipine33$1,849
ClopidogrelClopidogrel Bisulfate73$1,610
Ranolazine ErRanolazine16$1,419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$206,543166 claims
NovartisEntresto$15$41,12934 claims
AmgenCorlanor$418$3,22912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Royal Oak

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →